Skip to main content
Equibles
ONC logo

ONC · BeOne Medicines Ltd. · Metrics

Track ONC — free

Use ONC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ONC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$416.54 +0.58 (+0.14%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$47.58B
Shares
114.23M
Volume · Nov 13 345.46K Avg daily vol (3M) 404.68K

ONC metrics

111 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$416.54
Market cap
$47.58B

Price action

23 metrics
Price change (1W)
+2.4%
Price change (30D)
+11.4%
Price change (3M)
+19.9%
Price change (6M)
+42.0%
Price change (YTD)
+37.1%
Price change (1Y)
+13.1%
Trailing year
Price change (5Y)
+10.0%
52-week high
$424.00
52-week low
$260.27
Change from 52-week high
-1.8%
Change from 52-week low
+60.0%
Annualized volatility
34.2%
Annualized volatility (3M)
33.2%
Implied volatility (30D)
38.5%
IV rank (1Y)
28.3
IV percentile (1Y)
20.8
Beta
0.7
RSI (14D)
67.5
Price vs SMA 50
+12.8%
Price vs SMA 200
+27.1%
Avg volume (3M)
404,684
Relative volume
0.9
Average dollar volume
$149.96M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
114.23M

Valuation

12 metrics
P / E (TTM)
52.5
Trailing earnings · reciprocal yield 1.9%
PEG ratio
0.2
EV / revenue
6.5×
reciprocal yield 15.4%
EV / EBITDA
31.6×
reciprocal yield 3.2%
EV / EBIT
36.4×
reciprocal yield 2.7%
P / sales
7.2×
reciprocal yield 13.9%
P / book
8.2
reciprocal yield 12.2%
FCF yield
3.0%
TTM · current market cap
Buyback yield
—
P / FCF
32.8
reciprocal yield 3.0%
P / operating cash flow
29.9
reciprocal yield 3.3%
Earnings yield
1.9%

Historical valuation

8 metrics
P / E historical average (3Y)
189.3×
reciprocal yield 0.5%
P / E historical average (5Y)
189.3×
reciprocal yield 0.5%
EV / revenue historical average (3Y)
87.6×
reciprocal yield 1.1%
EV / revenue historical average (5Y)
129.1×
reciprocal yield 0.8%
EV / EBIT historical average (3Y)
1,059.6×
reciprocal yield 0.1%
EV / EBIT historical average (5Y)
1,059.6×
reciprocal yield 0.1%
EV / EBITDA historical average (3Y)
1,392.8×
reciprocal yield 0.1%
EV / EBITDA historical average (5Y)
1,392.8×
reciprocal yield 0.1%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
89.4%
Operating margin
17.8%
Trailing 12 months
Net margin
13.9%
Gross profit (TTM)
$5.91B
Operating profit (TTM)
$1.18B
Net income (TTM)
$915.57M
Trailing 12 months
Diluted EPS (TTM)
$7.93
FCF margin
21.9%
Effective tax rate
19.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$56.88
Gross profit per diluted share (TTM)
$50.85
Operating profit per diluted share (TTM)
$10.14
EBITDA per diluted share (TTM)
$11.67
Net income per diluted share (TTM)
$7.87
Operating cash flow per diluted share (TTM)
$13.69
Free cash flow per diluted share (TTM)
$12.47
Capital expenditures per diluted share (TTM)
$1.21
R&D per diluted share (TTM)
$20.92
Stock compensation per diluted share (TTM)
$4.45
Book value per share
$39.34

Growth

11 metrics
Revenue growth YoY
+33.8%
Year over year
Net income growth YoY
+208.2%
Revenue (TTM)
$6.61B
Trailing 12 months
EPS growth YoY
+212.5%
Shares change YoY
+2.4%
Year over year · more shares
Revenue CAGR (3Y)
+55.7%
Revenue CAGR (5Y)
+76.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
15.7%
Return on assets
9.3%
Debt / equity
0.2
Current ratio
3.6
EBITDA (TTM)
$1.36B
Free cash flow (TTM)
$1.45B
Quick ratio
3.2
Interest coverage
8.3
Net debt / EBITDA
-3.5
Return on invested capital
85.7%
Trailing 12 months
Net cash
$4.71B
Latest balance sheet
Cash & equivalents
$5.78B
Total assets
$9.88B
Total debt
$1.07B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.59B
Capital expenditures (TTM)
$140.96M
R&D (TTM)
$2.43B
SG&A (TTM)
$2.30B
Stock compensation (TTM)
$517.01M
R&D / revenue
36.8%
Stock compensation / revenue
7.8%

Ownership (13F)

9 metrics
13F filers
285
13F filer change QoQ
+2
Institutional ownership
30.8%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
1.0%
Private-fund adviser ownership
1.0%
Active holders' share change QoQ
-0.1%
Holder tenure
21.6
Price vs estimated holder cost
-2.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
1.4%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$48.49M
Insider-sentiment score
45 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1651308 CUSIP 07725L102 13F (30d) 269 filings 245 filers Visit website Investor relations